Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Relistor Injectable Product

PreclinicalSmall molecule

MMethodist Health System

1

Indications

2

Total Trials

1

Active Trials

0

Competitors

Timeline

Expected Milestones

Q3 2026

Therapeutics

NCT04787848

Clinical

Trials by Indication[1]

Therapeutics1 trial

Chronic Widespread Pain in HIV: Novel Mechanisms and Therapeutics

Recruiting·FFlorida International University·N/A·NCT04787848·200 enrolled

Constipation1 trial

RELISTOR's Effects on Opioid-Induced Constipation

Withdrawn·MMethodist Health System··NCT04930237

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Relistor Injectable Product. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Relistor Injectable Product compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Relistor Injectable Product. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Methodist Health System company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MMethodist Health System

Related News